验证中
本页为自动翻译。剂量和警告请以英文原文为准。 阅读英文版
首页 / 在尼日利亚注册 / Derm Chloramphenicol

Derm Chloramphenicol

NAFDAC注册号 B4-6227 药物

已在NAFDAC注册。注册有效As of 5 November 2026 · synced automatically from official sources.
产品
Derm Chloramphenicol
NAFDAC编号
B4-6227
活性成分
Chloramphenicol
强度
250 mg
年级
Capsule
包装规格
1 x 10's (in blister)
制造商
未上榜
申请人(持有人)
Derm Pharmaceuticals Limited
Approved
6 Jul 2023
Status
Active View on NAFDAC ↗
Registration valid to
5 Jul 2028
WHO提醒
None found
Community reports
None
Times checked
0

About the medicine: Chloramphenicol: uses, dosage and brands worldwide

What we found

  • Derm Chloramphenicol is on the NAFDAC register with an active registration (B4-6227). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Derm Chloramphenicol

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Serious warning: Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia and granulocytopenia) are known to occur after the administration of chloramphenicol. In addition, there have been reports of aplastic anemia attributed to chloramphenicol which later terminated in leukemia. Blood dyscrasias have occurred after both short-term and prolonged therapy with this drug. …
Children
  • Precaution should be used in therapy of premature and full-term
  • Neonates and infants to avoid “gray syndrome” toxicity
  • Due to immature metabolic processes in the neonate and infant, excessive blood levels may result from administration of the recommended dose
  • The dosage should be adjusted accordingly or, preferable, the blood concentration should be determined at appropriate intervals (see ADVERSE REACTIONS , "Gray Syndrome" )
  • See DOSAGE AND ADMINISTRATION for dosing information in the pediatric population
Older adults

Clinical studies of chloramphenicol sodium succinate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. …

Talk to a doctor first if
  • Chloramphenicol is contraindicated in individuals with a history of previous hypersensitivity and/or toxic reaction to it
  • It must not be used in the treatment of trivial infections or where it is not indicated, as in colds, influenza, infections of the throat; or as a prophylactic agent to prevent bacterial infections
Medicines it may not mix with

Concurrent therapy with other drugs that may cause bone marrow depression should be avoided.

Warnings

PRECAUTIONS: General Repeated courses of chloramphenicol treatment should be avoided if at all possible. Treatment should not be continued longer than required to produce a cure with little or no risk or relapse of the disease. Excessive blood levels may result from administration of the recommended dose to patients with impaired liver or kidney function. The dosage should be adjusted accordingly, or preferably, the blood concentration should be determined at appropriate intervals. The use of this antibiotic, as with other antibiotics, may result in an overgrowth of nonsusceptible organisms, including fungi. …

Possible side effects

Blood Dyscrasias The most serious adverse effect of chloramphenicol is bone marrow depression. Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, and granulocytopenia) are known to occur after the administration of chloramphenicol. An irreversible type of marrow depression leading to aplastic anemia with a high rate of mortality is characterized by the appearance weeks or months after therapy of bone marrow aplasia or hypoplasia. Peripherally, pancytopenia is most often observed, but in a small number of cases only one or two of the three major cell types (erythrocytes, leukocytes, platelets) may be depressed. …

Pregnancy and breastfeeding

Pregnancy Pregnancy Category C – Animal reproduction studies have not been conducted with chloramphenicol. There are no adequate and well-controlled studies to establish safety of this drug in pregnancy. It is not known whether chloramphenicol can cause fetal harm when administered to a pregnant woman. Orally administered chloramphenicol has been shown to cross the placental barrier. …

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2024-10-10.

Label for chloramphenicol, the active ingredient registered with NAFDAC.

NAFDAC recall & alert notices

Public Alert No. 05/2026 – Alert on the Mop-up of Counterfeit Dermazin (1% Silver Sulphadiazine) Cream6 Feb 2026 · nafdac.gov.ngThe National Agency for Food and Drug Administration and Control (NAFDAC) is alerting healthcare providers and the public about the circulation of counterfeit Dermazin (1% Silver Sulphadiazine) Cream.NAFDAC received a complaint from the legitimate Marketing Authorization Holder, Taylek Drugs Company Limited, concerning…Public Alert No. 005/2022- Recall of Dermaved Sensitive Cream (Unlicensed Medicine)10 Feb 2022 · nafdac.gov.ng, The National Agency for Food and Drug Administration and Control is informing healthcare providers that Medicines & Healthcare products Regulatory Agency (MHRA) in conjunction with Dermaved is recalling Dermaved Sensitive Cream due to presence of clobetasol propionate (0.001% w/w).   Clobetasol propionate is a strong…Public Alert No. 028/2020- Boots Company PLC Recalls Boots Dermacare 1% w/w Hydrocortisone Ointment, EL (20) A/47 (Batch Number: IDD) due to the presence of Pseudomonas aeruginosa12 Nov 2020 · nafdac.gov.ng, The National Agency for Food and Drug Administration and Control has been informed by the United Kingdom’s (UK) Medicine and Healthcare Product Regulatory Agency (MHRA) that Boots Company PLC has recalled Boots Dermacare 1% w/w Hydrocortisone Ointment, EL (20) A/47 (Batch Number: IDD) due to the presence of Pseudomon…

Compare the brands and batch numbers in these notices with your pack, or enter your batch number above.

Check your pack of Derm Chloramphenicol

Add the expiry date on your pack for a full Trust Score.

Or take photos of the pack
3 free checks left today Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

About Derm Chloramphenicol

What is in Derm Chloramphenicol?

Derm Chloramphenicol contains Chloramphenicol (250 mg), as capsule, according to its NAFDAC registration record.

Is Derm Chloramphenicol registered with NAFDAC?

Yes. Derm Chloramphenicol is listed on the NAFDAC register under registration number B4-6227, and its registration is active as of 5 November 2026.

Has Derm Chloramphenicol been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Derm Chloramphenicol in our automatically synced alert list.

How can I check that my pack of Derm Chloramphenicol is genuine?

Run a free authenticity scan with the NAFDAC number B4-6227, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Derm Chloramphenicol? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.